Key facts
- Pickcells’s last known valuation is $640K (Apr 2023).
- It has raised $680K; the latest was Seed Round ($20K) in Dec 2024.
- Notable investors include KPTL, Artemisia, Biominas Brasil, Brazil Accelerate 2030, InovaHC.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pickcells
- ·The full record, as it builds
Funding rounds
No funding rounds for Pickcells are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pickcells
Developer of an AI-powered diagnostic platform designed to optimize workflows and increase accuracy across clinical and laboratory environments. The company's platform offers automated slide analysis, cloud-based biorepositories, and integrated software-hardware systems, enabling hospitals, pathology labs, and healthcare professionals to accelerate diagnostics, reduce manual effort, and improve decision-making.
- Sector
- Healthcare
- HQ
- Recife, Brazil
- Founded
- 2014
- Employees
- 15
- Website
- pickcells.bio/
- Ownership
- Privately Held (backing)
Pickcells doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pickcells shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pickcells in its N-PORT filings yet. We sweep new filings monthly.